DAFTAR PUSTAKA

1. Lambrecht BN, Hammad H. The immunology of asthma. Nature

immunology 2015; 16 (1): 45–56

2. Barnes PJ. Pathophysiology of asthma. Eur Respir Mon. 2003, 23: 84–
113.

3. National Heart Lung Blood Institute (NHLBI). Definition,

pathophysiology and pathogenesis of asthma, and natural history of
asthma. 2007: 11–28.

4. Brusselle, G.G., Maes, T. & Bracke, K.R. Eosinophils in the spotlight:

eosinophilic airway inflammation in nonallergic asthma. Nat. Med. 2013:
19, 977–9.

5. Murray JF, Nadel JA, Broaddus VC. Asthma: Pathogenesis and

phenotypes. Murray & Nadel’s Textbook of Respiratory Medicine sixth
edition. 2016 (2): 713–725.

6. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary

disease. Immunology. 2008 (8): 183–191.

7. Boushey HA. Drugs Used in Asthma. In: Katzung BG. Basic & Clinical
Pharmacology 14th edition. 2017. United States of America: Lange
medical, pp. 339-53.

8. Abbas A, Shahid S, Sabah A, et al. The Clinical Complications of Asthma

and its Pharmacotherapy. BBB. 2014, 2(1): 117-46.

9. Zdanowicz MM. Pharmacotherapy of Asthma. American Journal of

Pharmaceutical Education. 2007, 71 (5): 1-11

10. Barnes PJ. Inhaled Corticosteroids. Pharmaceuticals. 2010, 3: 514-40.

11. Tse SM, Tantisira K, Weiss ST. The Pharmacogenetics and

Pharmacogenomics of Asthma Therapy. The Pharmacogenomics Journal.
2011, 11:383-92.

12. Tamm M, Richards DH, Beghe B, Fabbri L. Inhaled corticosteroid and

long-acting b2-agonist pharmacological profiles: effective asthma therapy
in practice. Respiratory Medicine. 2012, 106(1): 9–19.

13. William DM. Clinical pharmacology of corticosteroids. Respiratory Care.

2018, 63(6): 665-8.
14. Bollmeier SG. New Therapies in Asthma. ACSAP. 2013: 1-27

15. Pavord, ID, Korn S, Howarth P, et al. Mepolizumab for severe

eosinophilic asthma (DREAM): a multicenter, double-blind, placebo-
controlled trial. Lancet 2012;380:651-9.